<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="179374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00759785</url>
  </required_header>
  <id_info>
    <org_study_id>0646-013</org_study_id>
    <secondary_id>MK0646-013</secondary_id>
    <secondary_id>2008_554</secondary_id>
    <nct_id>NCT00759785</nct_id>
  </id_info>
  <brief_title>A Study of Dalotuzumab (MK0646) in Breast Cancer Patients (0646-013)</brief_title>
  <official_title>A Study to Establish Proof-of-Biology for MK0646 in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the response of growth factor signatures to a single dose of Dalotuzumab
      in patients with stage I-IIIa breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dalotuzumab will induce a decrease in the growth factor signature.</measure>
    <time_frame>Following single dose of study drug infused over 60 - 120 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in detectable expression of IGF1R in tumors</measure>
    <time_frame>Following single dose of study drug infused over 60 - 120 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalotuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Dalotuzumab (MK0646)</intervention_name>
    <description>Single dose of Dalotuzumab 20 mg/kg infused over 60 - 120 minutes.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0646</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has operable stage I-IIIa breast cancer of the following subtypes: (1)
             ER-negative, PR-negative, and HER2-negative breast cancer; (2) ER-positive tumor
             meeting one of the following criteria- histologic grade 3; histologic grade 2 and
             PR-negative; histologic grade 2 and Ki67&gt; 10%. Tumor is at least 2 cm in diameter as
             assessed by physical or radiographic exam

          -  Patient is female and &gt; 18 years of age

        Exclusion Criteria:

          -  Patient is pregnant, breastfeeding or planning to become pregnant while in the study

          -  Patient has received prior chemotherapy, biological therapy or radiation

          -  Patient has participated in a clinical trial in the last 30 days

          -  Patient has a history of drug or alcohol abuse in the last year

          -  Patient is HIV positive. Patient has a history of Hepatitis B or C

          -  Patient has poorly controlled diabetes mellitus.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 24, 2015</lastchanged_date>
  <firstreceived_date>September 24, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
